Shares in Eli Lilly have weakened after CVS Health, one of the largest pharmacy benefit managers (PBMs) in the US, said it ...

The application has been submitted by the capital investment arm of insurance company Aviva and mixed-use developer Socius, ...

A new policy from the NIH in the US will cut billions of dollars of funding for research organisations and hospitals outside ...

GSK has highlighted approval of Nucala in COPD as one of its top 2025 priorities, adding to its established medicines for the ...

Informed consent is a foundational element of every clinical trial. Yet, the traditional paper-based process has long been ...

It can take up to 15 years for a new drug to reach the market, and with only 20% of pharmaceutical professionals adopting AI, ...

According to the WSJ, the universal vaccine project is being pioneered by two recently appointed senior scientists in the NIH ...

It isn't the first drug in the class to be cleared by the FDA for gMG – Argenx and UCB have FcRn blockers already on the ...

How does market access impact the pharmaceutical commercialisation journey, and what role does it play in driving success ...

According to NICE's Early Value Assessment (EVA) guidance on the technology, automated use of DERM "could result in more ...

Despite these benefits, biosimilar medicines remain under-recognised and underused in many markets. Real-world uptake often ...

Here, we trace RWE's remarkable evolution from its handwritten roots through technological breakthroughs, methodological advancements, and regulatory milestones that have collectively elevated ...